CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 36 enrolled
Drug / intervention
Nelfinavir Mesylate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03077451
NCT03077451Phase 2Completed
CompareCT.gov

A Pilot Study of Nelfinavir for the Treatment of Kaposi Sarcoma

AIDS Malignancy Consortium·interventional·Posted Mar 13, 2017·Updated Dec 17, 2025

In Brief

A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis and Nelfinavir Mesylate for Recurrent Kaposi Sarcoma and Skin Kaposi Sarcoma. Completed, enrolled 36 participants across 12 sites in 3 countries.

Detailed Summary

This pilot phase II trial studies how well nelfinavir mesylate works in treating patients with kaposi sarcoma. Nelfinavir mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Kaposi Sarcoma, Skin Kaposi Sarcoma
CountriesSouth Africa, Uganda, United States
CollaboratorsNational Cancer Institute (NCI), The Emmes Company, LLC, University of Arkansas, University of California, Los Angeles, AIDS and Cancer Specimen Resource, Montefiore Medical Center

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedMar 13, 2017
Enrollment StartMar 13, 2017
Primary CompletionMay 23, 2022
Study CompletionApr 13, 2023
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 9.3 years ago

Interventions

Laboratory Biomarker Analysisother

Correlative studies

Nelfinavir Mesylatedrug

Given PO